Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2007 May 15;109(10):4470-7. Epub 2007 Jan 25.

2.

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr.

N Engl J Med. 2003 Dec 25;349(26):2483-94.

3.

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD Jr, Zhan F.

Blood. 2010 Jan 7;115(1):61-70. doi: 10.1182/blood-2009-03-210526. Epub 2009 Oct 16.

4.

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.

Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr.

Bone. 2008 Apr;42(4):669-80. doi: 10.1016/j.bone.2007.12.006. Epub 2007 Dec 27.

PMID:
18294945
5.

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.

Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, Thomassen M, Kerndrup GB, Rasmussen T.

Br J Haematol. 2008 Jan;140(1):25-35. Epub 2007 Nov 12.

PMID:
18005268
6.

Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.

Kocemba KA, Groen RW, van Andel H, Kersten MJ, Mahtouk K, Spaargaren M, Pals ST.

PLoS One. 2012;7(2):e30359. doi: 10.1371/journal.pone.0030359. Epub 2012 Feb 17.

7.

Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.

Kristensen IB, Christensen JH, Lyng MB, Møller MB, Pedersen L, Rasmussen LM, Ditzel HJ, Abildgaard N.

Leuk Lymphoma. 2014 Apr;55(4):911-9. doi: 10.3109/10428194.2013.820288. Epub 2013 Aug 5.

PMID:
23915193
8.

Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.

Zhou F, Meng S, Song H, Claret FX.

Blood Rev. 2013 Nov;27(6):261-7. doi: 10.1016/j.blre.2013.08.002. Epub 2013 Sep 2. Review.

9.

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.

Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2008 Jul 1;112(1):196-207. doi: 10.1182/blood-2008-01-132134. Epub 2008 Feb 27.

10.

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI.

J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104.

11.

Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.

Park BM, Kim EJ, Nam HJ, Zhang D, Bae CH, Kang M, Kim H, Lee W, Bogen B, Lim SK.

Yonsei Med J. 2017 May;58(3):505-513. doi: 10.3349/ymj.2017.58.3.505.

12.

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.

Fowler JA, Mundy GR, Lwin ST, Edwards CM.

Cancer Res. 2012 May 1;72(9):2183-9. doi: 10.1158/0008-5472.CAN-11-2067. Epub 2012 Feb 28.

13.

Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.

Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L, Chang H.

PLoS One. 2012;7(1):e30215. doi: 10.1371/journal.pone.0030215. Epub 2012 Jan 20.

14.

Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas.

Papachristou DJ, Batistatou A, Sykiotis GP, Varakis I, Papavassiliou AG.

Bone. 2003 Apr;32(4):364-71.

PMID:
12689679
15.

JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.

Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, Yoneda T.

J Bone Miner Res. 2008 Jun;23(6):907-14. doi: 10.1359/jbmr.080211.

16.

[Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].

Dun XY, Jiang H, Hou J.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Sep;38(5):453-8. Chinese.

PMID:
19830856
17.

Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway.

Knobloch J, Shaughnessy JD Jr, Rüther U.

FASEB J. 2007 May;21(7):1410-21. Epub 2007 Feb 5.

PMID:
17283219
18.

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Manni S, Carrino M, Manzoni M, Gianesin K, Nunes SC, Costacurta M, Tubi LQ, Macaccaro P, Taiana E, Cabrelle A, Barilà G, Martines A, Zambello R, Bonaldi L, Trentin L, Neri A, Semenzato G, Piazza F.

Oncotarget. 2017 Feb 28;8(9):14604-14619. doi: 10.18632/oncotarget.14654.

19.

Sclerostin is overexpressed by plasma cells from multiple myeloma patients.

Brunetti G, Oranger A, Mori G, Specchia G, Rinaldi E, Curci P, Zallone A, Rizzi R, Grano M, Colucci S.

Ann N Y Acad Sci. 2011 Nov;1237:19-23. doi: 10.1111/j.1749-6632.2011.06196.x.

PMID:
22082361
20.

Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.

Semin Oncol. 2001 Dec;28(6):607-12. Review.

PMID:
11740818

Supplemental Content

Support Center